The
CLINUVEL Group
We are a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for the general population.
What is a Stroke?
Strategic Update IV
On 13 May 2022 CLINUVEL announced its fourth Strategic Update, focused on the Group’s view to establish a sustainable group of companies.
Latest News
Confirming the potential of our products
to repair UV-induced DNA damage
Evaluating afamelanotide
as treatment for AIS
Pioneering the concept of
medicinal photoprotection
We aim to grow our knowhow continuously
and establish a learned community
doses of SCENESSE® administered
>1,400 individuals have received SCENESSE®
Pharmaceutical Technology
Melanocortins
CLINUVEL is developing novel pharmaceuticals with known photoprotective, antioxidative, anti-inflammatory, vasoactive and anti-oncotic properties. Read more.
Alpha-Melanocyte Stimulating Hormone (α-MSH)
A naturally occurring peptide hormone which is released by skin cells in response to the stimulation by ultraviolet radiation (UVR). Afamelanotide is a synthetic analogue of α-MSH. Click here to read more.
Approved products
Read more about SCENESSE® (afamelanotide 16mg) CLINUVEL's proprietary first-in-class-drug.
Photomedicine
Light and the
Environment
CLINUVEL is a leader in the field of photomedicine, investigating the interaction of light and human biology and pioneering the concept of medicinal photoprotection – protecting skin from light. The concentration of resources and efforts on photomedicine has made CLINUVEL a leader in the field.
DNA Repair
DNA Repair Program:
Xeroderma Pigmentosum
XP patients exhibit extreme deficiency in repair of UV-provoked damage to the DNA helix within the nucleus of skin cells. If left unrepaired, damaged DNA replicates and significantly increases the risk of skin cancers, including melanoma, in these patients.
Media Coverage
Media coverage on third-party sites can be found at the links below (please note that subscriptions may be required):
Contact